LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

NeuroOne® Medical to Report First Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on February 14

February 09, 2023 | Last Trade: US$0.58 0.02 2.73

EDEN PRAIRIE, Minn., Feb. 9, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal first quarter 2023 ended December 31, 2022 and provide a corporate update on February 14, 2023 at 4:30 PM Eastern Time.

Conference Call and Webcast Information:

Tuesday, February 14, 20234:30 PM Eastern Time

Participant Dial-In:
877-405-1216 / 201-689-8336

Live Webcast: 
Join here

Phone Replay:
877-660-6853 / 201-612-7415, Access ID: 13736384; available through February 28, 2023

Webcast Replay:       
Available for 12 months

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.  For more information, visit nmtc1.com

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page